^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Neuroendocrine Tumor

    Apply
    Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) (NCT04086485)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/03/2022
    Primary completion :
    07/01/2025
    Completion :
    01/01/2026
    BRCA • SSTR
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCI-2018-01054) (NCT03360721)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/06/2018
    Primary completion :
    04/30/2027
    Completion :
    04/30/2027
    PTEN
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • prednisone • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (NCT06406465)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    07/30/2027
    Completion :
    07/30/2028
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/13/2019
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    PD-L1 • CD4
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (A021804) (NCT04394858)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/17/2021
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    MGMT • CD4
    |
    Lynparza (olaparib) • temozolomide
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727)
    Phase 1/2
    Harpoon Therapeutics, Inc., a subsidiary of Mer...
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/14/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (NCT04750954)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/22/2021
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    SSTR
    |
    SSTR Expression
    |
    peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)
    Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (NCT04665739)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/03/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    SSTR
    |
    cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) (NCT04709276)
    Phase 2
    Andrew J. Armstrong, MD
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/07/2021
    Primary completion :
    12/01/2025
    Completion :
    06/01/2028
    TP53 • PTEN • RB1 • SYP
    |
    LDH elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/22/2015
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit (NCT06805825)
    Phase 1
    Novelty Nobility, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    02/03/2025
    Primary completion :
    08/30/2027
    Completion :
    12/31/2027
    KIT
    |
    NN3201
    A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (CHM-2101-001) (NCT06055439)
    Phase 1/2
    Chimeric Therapeutics
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/15/2024
    Primary completion :
    05/01/2026
    Completion :
    05/01/2027
    CDH17
    |
    CDH1 expression
    |
    cyclophosphamide
    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) (LITESPARK-015) (NCT04924075)
    Phase 2
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/12/2021
    Primary completion :
    06/04/2029
    Completion :
    06/04/2029
    KIT • PDGFRA • VHL • EPAS1
    |
    PDGFRA mutation
    |
    Welireg (belzutifan)
    Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) (NCT06717243)
    Phase N/A
    Oncology Center of Biochemical Education And Re...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/20/2025
    Primary completion :
    03/20/2028
    Completion :
    12/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    ATRX/DAXX in EUS-FNB Specimens of Pan-NETs (FORESEE) (NCT06406387)
    Phase N/A
    Azienda Ospedaliera Universitaria Integrata Verona
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/01/2024
    Primary completion :
    03/30/2025
    Completion :
    11/30/2029
    ATRX • DAXX
    Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/07/2025
    Initiation :
    08/03/2012
    Primary completion :
    11/29/2018
    Completion :
    09/01/2020
    ER • AFP
    |
    Istodax (romidepsin)
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (NCT05879978)
    Phase 1/2
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/28/2023
    Primary completion :
    09/05/2025
    Completion :
    09/05/2025
    DLL3
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (NCT01841736)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/20/2013
    Primary completion :
    03/05/2019
    Completion :
    09/13/2025
    CHGA
    |
    pazopanib
    Dual-Tracer Theranostic PET (NCT05680675)
    Phase N/A
    University of Utah
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    12/08/2022
    Primary completion :
    06/04/2024
    Completion :
    06/04/2024
    SSTR
    |
    SSTR positive
    Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH) (NCT04954820)
    Phase 2
    Institut du Cancer de Montpellier - Val d'Aurelle
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/18/2021
    Primary completion :
    10/01/2031
    Completion :
    10/01/2031
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)
    Using Novel Imaging to More Safely Treat Neuroendocrine Tumors (NCT06122610)
    Phase 1
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2025
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    SSTR
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (NCT03206060)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    10/10/2017
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    NF1 • VHL • SSTR
    |
    RET mutation • VHL mutation
    |
    Lutathera (lutetium Lu 177 dotatate)
    Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (NCT05691465)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    12/27/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    TP53 • PTEN • RB1 • SYP • CHGA
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/05/2023
    Primary completion :
    12/01/2027
    Completion :
    08/01/2028
    EGFR • DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)
    A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (PELICAN) (NCT06232564)
    Phase 2
    Imperial College London
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    07/08/2024
    Primary completion :
    03/02/2028
    Completion :
    08/02/2028
    PD-1 • VEGFA • CD34 • FOXP3
    |
    Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV
    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (NCT04919226)
    Phase 3
    ITM Solucin GmbH
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/21/2021
    Primary completion :
    06/01/2027
    Completion :
    09/01/2027
    SSTR
    |
    SSTR positive
    |
    5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
    Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) (NCT05636618)
    Phase 1/2
    Perspective Therapeutics
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/27/2023
    Primary completion :
    11/26/2029
    Completion :
    12/26/2029
    SSTR • CD4 • SSTR2
    |
    SSTR2 expression • SSTR2 positive
    |
    VMT-𝛼-NET
    At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer (NCT05969860)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    08/23/2023
    Primary completion :
    06/14/2025
    Completion :
    06/14/2025
    HER-2
    |
    HER-2 positive
    Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) (NCT05477576)
    Phase 3
    RayzeBio, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/24/2022
    Primary completion :
    12/01/2025
    Completion :
    07/01/2028
    SSTR
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
    Avelumab in G2-3 NET (NET-002) (NCT03278379)
    Phase 2
    Sunnybrook Health Sciences Centre
    Completed
    Last update posted :
    12/24/2024
    Initiation :
    11/15/2017
    Primary completion :
    07/26/2021
    Completion :
    07/06/2023
    PD-L1 • TMB
    |
    Bavencio (avelumab)
    Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery (NCT04609592)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    10/28/2024
    Initiation :
    03/17/2021
    Primary completion :
    03/01/2025
    Completion :
    09/01/2027
    SSTR
    |
    PGR expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    Clinical-pathological Evaluation of Pit-NETs (PitNET2024) (NCT06607198)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Not yet recruiting
    Last update posted :
    09/23/2024
    Initiation :
    10/01/2024
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    SSTR
    Pembrolizumab with Combination Chemotherapy in Treating Participants with Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (NCI-2018-01120) (NCT03582475)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    12/20/2018
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • etoposide IV
    Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC) (NCT04848337)
    Phase 2
    University of Michigan Rogel Cancer Center
    Recruiting
    Last update posted :
    08/14/2024
    Initiation :
    05/25/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    SYP • CHGA
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) (NCT05987176)
    Phase 2
    Imperial College London
    Recruiting
    Last update posted :
    08/09/2024
    Initiation :
    08/02/2024
    Primary completion :
    09/01/2028
    Completion :
    03/30/2029
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)
    A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (NCT02923934)
    Phase 2
    Olivia Newton-John Cancer Research Institute
    Completed
    Last update posted :
    07/24/2024
    Initiation :
    08/22/2017
    Primary completion :
    04/27/2020
    Completion :
    12/12/2023
    MSI
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (NCT06041516)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/19/2024
    Primary completion :
    10/30/2027
    Completion :
    10/30/2029
    CD4
    |
    ADCT-701